Transposons are segments of DNA that can move from one location to another within a genome. They come in two main types, each using a fundamentally different strategy: one cuts itself out and pastes into a new spot, while the other copies itself through an RNA intermediate, leaving the original in place. Together, these mobile elements make up at least 46% of the human genome, making them far more common than the genes that code for proteins.
Cut-and-Paste: How DNA Transposons Move
Class II transposons, called DNA transposons, are the simpler of the two types. They work through a “cut-and-paste” mechanism, physically removing themselves from one location and inserting into another. The key player is an enzyme called transposase, which the transposon itself encodes.
The process starts when two transposase molecules recognize and bind to short sequences at each end of the transposon, called terminal inverted repeats. These are like bookends that mark where the transposon begins and ends. The transposase molecules then cut both strands of DNA at each end, freeing the transposon from its original location. The two transposase molecules join together into a pair, holding both ends of the now-freed transposon and forming what researchers call a paired-end complex.
This complex then finds a new target site in the genome. For one common family of DNA transposons, the target is any spot where the letters T and A sit next to each other, which means there are millions of possible landing sites. The transposase inserts the transposon by attacking the target DNA with the free ends of the element, stitching it into its new home. The cell’s own DNA repair machinery fills in small gaps left at the insertion site, creating short duplicate sequences that flank the transposon like genetic fingerprints of the event. Because the element is physically moved rather than copied, the total number of DNA transposons in a genome stays roughly constant over time.
Copy-and-Paste: How Retrotransposons Spread
Class I transposons, called retrotransposons, use a completely different strategy. Instead of cutting themselves out, they make a copy through an RNA intermediate. The original stays put while the copy inserts somewhere new. This means every jump increases the total number of copies in the genome, which is why retrotransposons have accumulated in enormous numbers over evolutionary time.
The process begins like normal gene expression: the cell reads the transposon’s DNA and transcribes it into RNA. What happens next depends on the type of retrotransposon, but the most common variety in humans (called LINEs, for long interspersed elements) uses a process called target-primed reverse transcription. A protein encoded by the LINE element cuts one strand of the target DNA at the new location, then uses the cut end as a starting point to reverse-transcribe its RNA back into DNA, directly at the insertion site. A second cut on the opposite strand allows the second DNA strand to be built, resulting in a complete new copy of the element integrated into the genome.
LINEs are “autonomous,” meaning they carry the genetic instructions for the enzymes they need to copy themselves. But the human genome also contains over a million copies of a shorter element called Alu, which is only about 300 base pairs long. Alu elements are parasites of parasites: they don’t encode their own copying machinery and instead hijack the enzymes made by LINE elements to insert themselves into new locations. Despite their dependence on borrowed machinery, Alu elements have been spectacularly successful, occupying about 11% of the entire human genome. They are found only in primates and originally evolved from a small RNA involved in protein trafficking within cells.
How Cells Keep Transposons in Check
If transposons jumped freely, they would quickly destroy essential genes and make a genome unstable. Cells have evolved multiple layers of defense to keep them quiet. The most important is DNA methylation, a chemical modification that acts like a lock on the transposon’s DNA, preventing it from being read into RNA in the first place. In mammals, this methylation-based silencing is the primary way transposon activity is restrained.
A second line of defense involves small RNA molecules called piRNAs, which are especially active in reproductive cells. These tiny RNAs are built to match transposon sequences. They guide specialized proteins to find and destroy transposon RNA in the cell’s cytoplasm before it can be reverse-transcribed and reinserted. In the nucleus, piRNAs can also direct the addition of DNA methylation marks onto transposon sequences, reinforcing the long-term silencing. This two-pronged system, destroying active transposon RNA while also locking down the DNA source, keeps transposons under tight control during the critical window when reproductive cells are developing and the genome is most vulnerable.
What Happens When a Transposon Lands in the Wrong Place
When transposons do escape these controls, the consequences can be serious. A transposon inserting into the middle of a gene can disrupt it entirely, and insertions near genes can alter how much protein a gene produces. In humans, transposon insertions have been linked to cases of hemophilia, where a LINE element disrupted a gene needed for blood clotting. Researchers have also used engineered transposon systems in mice to systematically identify cancer-related genes by letting transposons jump throughout the genome and observing which disruptions lead to tumors. These screens have identified genes involved in more than twenty types of cancer, including liver, lung, breast, pancreatic, brain tumors, and several types of leukemia and lymphoma.
How Transposons Shaped Human Evolution
Not all transposon activity has been harmful. Over millions of years, some transposon insertions have been “domesticated” by the genome, repurposed into useful functions. The most striking example is the adaptive immune system. The mechanism your body uses to shuffle gene segments and produce billions of different antibodies, called V(D)J recombination, evolved from an ancient transposon. The enzyme that cuts and rearranges antibody genes uses the same fundamental chemistry as a transposase. Over evolutionary time, this domesticated transposon acquired safety features: mutations that prevent it from reinserting DNA randomly, and a requirement that both cuts happen simultaneously, which reduces the chance of dangerous chromosomal rearrangements. The result is a precisely controlled system that generates immune diversity without destabilizing the genome.
Transposon-derived sequences have also been co-opted as regulatory elements that control when and where genes are turned on, contributing new switches to the genome’s control architecture. Because transposons can spread copies of regulatory sequences to many locations at once, they have been a powerful engine for evolving new patterns of gene expression.
Transposons as Tools in Medicine
The same properties that make transposons effective at inserting DNA into genomes have made them attractive tools for gene therapy. The Sleeping Beauty transposon system, synthetically reconstructed from ancient, inactive transposon sequences found in fish genomes, is the most developed non-viral vector for delivering therapeutic genes into human cells. It works by combining two components: a transposon carrying the desired gene and a source of transposase enzyme. When both are delivered into a cell, the transposase inserts the therapeutic gene into the genome, where it can be expressed long-term.
Sleeping Beauty has been used in animal models to treat hemophilia, sickle cell anemia, and a severe skin blistering condition called epidermolysis bullosa. Its most advanced clinical application has been engineering immune cells to recognize and attack cancer. In this approach, T cells are removed from a patient, modified with Sleeping Beauty to carry a receptor that targets a protein found on lymphoma cells, and then returned to the patient. Compared to viral vectors, transposon-based systems are cheaper to manufacture, carry lower risks of triggering immune reactions, and can deliver larger genetic payloads, though they integrate somewhat randomly into the genome rather than at a precise target site.